

## Rubeola IgG, Mumps IgG, and Varicella IgG Testing Changes

**Effective Tuesday, June 20, 2023**, Rubeola IgG, Mumps IgG, and Varicella IgG moved platforms for testing. In addition, testing will now be performed at both ACL central laboratories. There are no changes in specimen collection or transport requirements.

**Collect:** SST tube

**Volume:** 1.0 mL serum optimal, 0.5 mL minimum.

**Transport:** refrigerated

**Performed:** Weekdays

The cutoff values for these tests will change. See chart below for additional information.

Test Name	Test Order Code	Former Cut-Off/ Interpretation	Cutoff/ Interpretation Effective 6.20.2023	Former ACL performing laboratory*	ACL performing laboratory* Effective 6.20.2023
<b>Rubeola Immunity IgG</b>	LAB8553	Neg $\leq$ 0.9: Not Immune Equiv. 0.91-1.09: Not immune Pos $\geq$ 1.10: Immune	<16.5 Non-immune $\geq$ 16.5 Immune	WCL	ICL WCL
<b>Mumps Immune Antibody IgG</b>	LAB8542	Neg $\leq$ 0.9: Not Immune Equiv. 0.91-1.09: Not immune Pos $\geq$ 1.10: Immune	<11.0 Non-immune $\geq$ 11.0 Immune	ICL	ICL WCL
<b>Varicella Zoster Immunity IgG</b>	LAB8230	Neg $\leq$ 0.9: Not Immune Equiv. 0.91-1.09: Not immune Pos $\geq$ 1.10: Immune	<165 Non-immune $\geq$ 165 Immune	WCL	ICL WCL

\*WCL – Wisconsin Central Laboratory | ICL – Illinois Central Laboratory

Any questions should be directed to ACL Client Services Department or Ken Copeland, PhD, Clinical Laboratory Director, ACL Laboratories. [Kenneth.copeland@aah.org](mailto:Kenneth.copeland@aah.org)

## In-house Stool Elastase Testing

**Effective Tuesday, June 20, 2023**, ACL's Wisconsin Central Laboratory began offering Pancreatic Elastase, Stool testing in-house. Testing will be performed on the Diasorin Liaison XL platform.

**Collect:** Stool - Random in a sterile cup.

**Volume:** 5.0 g (Min: 1.0 g) stool

**Transport:** refrigerated unpreserved in a sterile cup.

**Performed:** Tuesday-Saturday

Test Name	Test Order Code	Cutoff Effective 6.20.2023	ACL Performing laboratory
<b>Pancreatic Elastase, Stool</b>	LAB11651  (Replaces LAB9741)	<100 ug/g - Severe exocrine pancreatic insufficiency 100-199 ug/g - Mild to moderate exocrine pancreatic insufficiency >= 200 ug/g - Normal	Wisconsin Central Laboratory

## Cystic Fibrosis Carrier Screening Update (Test Order Code CFCS / LAB11337)

**Effective Tuesday, June 20, 2023**, ACL Laboratories implemented the following changes to Cystic Fibrosis Carrier Screening:

1. Updated test name: Cystic Fibrosis Mutation Panel (139 mutations)
2. Reporting time: Changed to 14 days
3. Test is available as single test (Test Order Code LAB11337) and as Prenatal Carrier Screen Panel (Test Order Code LAB10171).
  - a. Prenatal Carrier Screen Panel (Test Order Code LAB10171) also includes Fragile X Diagnosis (Test Order Code LAB9926) and Spinal Muscular Atrophy (SMA) Copy Number Analysis (Test Order Code LAB10172).

For additional information, please contact:

ACL Laboratories Molecular Pathology Department at 847-349-7182,

Michael Mihalov, MD - Medical Director at 847-349-7401, or

Lech Mazur, MS - Technical Director at 847-349-7185

## ACL Offers New Orderable Code for Pregabalin Level, Urine

**Effective Tuesday, June 20, 2023**, ACL Laboratories began offering Pregabalin Level, Urine (Test Order Code LAB11730) as an orderable test. Testing will be performed at ARUP Laboratories. Providers and clients will no longer have to utilize a Miscellaneous test code for ordering. Refer to the table below for detailed assay information.

Test Information	Pregabalin Level, Urine Test Order Code LAB11730
Specimen Type	Random Urine
Collection Tube	Sterile Cup
Temperature	Refrigerated
Stability	1 month
Methodology	Quantitative Liquid Chromatography-Tandem Mass Spectrometry
TAT	3-8 days
Performing Lab	ARUP

## ACL Offers New Orderable Code for Zolpidem Level, Urine, Quantitative

**Effective Tuesday, June 20, 2023**, ACL Laboratories began offering Zolpidem Level, Urine, Quantitative (Test Order Code LAB11731) as an orderable test. Testing will be performed at ARUP Laboratories. Providers and clients will no longer have to utilize a Miscellaneous test code for ordering. Refer to the table below for detailed assay information.

Test Information	Zolpidem Level, Urine Test Order Code LAB11731
Specimen Type	Random Urine
Collection Tube	Sterile Cup
Temperature	Refrigerated
Stability	1 month
Methodology	Quantitative Liquid Chromatography-Tandem Mass Spectrometry
TAT	3-6 days
Performing Lab	ARUP

## ACL Deactivates Select Hereditary Cancer Genetic Test Order Codes

**Effective Tuesday, June 20, 2023**, following the Natera EPIC interface go-live and overall low utilization, ACL will no longer offer orderable test codes for the following hereditary cancer assays.

- BRCA1 and 2, Sequencing and Deletion Duplication Analysis (Test Order Code LAB9406)
- Breast or Ovarian Cancer Panel (Test Order Code LAB9407)
- Colorectal Cancer Panel (Test Order Code LAB9462)
- Comprehensive Cancer Panel (Test Order Code LAB9471)
- High or Moderate Risk Panel (Test Order Code LAB9583)

Replacement assays, performed by Natera, are available in Epic for Advocate Health Midwest providers. Please refer to the table below for additional details.

Deactivated Effective Tuesday, June 20, 2023	Replacement Test Effective Immediately	Genes Assessed
BRCA1 and 2, Sequencing and Deletion Duplication Analysis (LAB9406)	Empower BRCA (2) (LAB11457)	<i>BRCA1, BRCA2</i>
Breast or Ovarian Cancer Panel (LAB9407)	Empower GYN Guidelines (2+17) (LAB11459)	<i>ATM, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, NBN, NF1, PALB2, PMS2, PTEN, RAD51C, RAD51D, STK11, TP53</i>
Colorectal Cancer Panel (LAB9462)	Empower Lynch Multi-CNCR (5+35) (LAB11482)	<i>MLH1, MSH2, MSH6, PMS2, EPCAM, APC, ATM, AXIN2, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, GALNT12, GREM1, HOXB13, MEN1, MITF, MSH3, MUTYH, NBN, NF1, NTHL1, PALB2, POLD1, POLE, PTEN, RAD51C, RAD51D, RNF43, RPS20, SMAD4, STK11, TP53, VHL</i>
Comprehensive Cancer Panel (LAB9471)	Empower Comprehensive (2+79) (LAB11486)	<i>AIP, ALK, APC, ATM, AXIN2, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDC73, CDH1, CDK4, CDKN1B, CDKN1C, CDKN2A, CEBPA, CHEK2, CYLD, DDX41, DICER1, EGFR, EPCAM, EXT1, EXT2, FH, FLCN, GATA2, GREM1, HOXB13, KIT, LZTR1, MAX, MEN1, MET, MITF, MLH1, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NF2, NTHL1, PALB2, PDGFRA, PHOX2B, PMS2, POLD1, POLE, POT1, PRKAR1A, PTCH1, PTEN, RAD51C, RAD51D, RB1, RET, RHBDF2, RUNX1, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, STK11, SUFU, TERC, TERT, TMEM127, TP53, TSC1, TSC2, VHL, WT1</i>
High or Moderate Risk Panel (LAB9583)	Empower Multi-Cancer (2+38) (LAB11460)	<i>APC, ATM, AXIN2, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, GALNT12, GREM1, HOXB13, MEN1, MITF, MLH1, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NTHL1, PALB2, PMS2, POLD1, POLE, PTEN, RAD51C, RAD51D, RNF43, RPS20, SMAD4, STK11, TP53, VHL</i>